Efalizumab clinical trials
How each study uses efalizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 27 Oct 2003 · Raptiva · BLA 125075 (FDA, Purple Book)
- European Union
- 20 Sept 2004 · Raptiva · EMEA/H/C/000542 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
33 studies that test it; most in 2008 (8)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 4 |
| 2003 | 4 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 7 |
| 2007 | 4 |
| 2008 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 19
Genentech, Inc. (10) · Merck KGaA, Darmstadt, Germany (4) · University of California, San Francisco (2) · XOMA (US) LLC (2) · Emory University (2) · Rockefeller University (1) · Oregon Health and Science University (1) · University of California, Davis (1)
Often tested with
Tested in the same studies.
Ranibizumab (2) · Abatacept (1) · Sirolimus (1) · Acitretin (1)
Studies
Open first, then newest update. How each study uses efalizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 35
- Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3Rockefeller UniversityNCT00115076Written as EfalizumabHow we know
- Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes MellitusCompletedPhase 1/2University of California, San FranciscoNCT00501709Written as Belatacept and RaptivaHow we know
- Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With RaptivaWithdrawnPhase 2The Cleveland ClinicNCT00308204Written as RaptivaHow we know
- Efalizumab for Moderate to Severe Atopic DermatitisCompletedPhase 1Oregon Health and Science UniversityNCT00226057Written as RaptivaHow we know
- Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases EfficacyCompletedPhase 1/2University of California, DavisNCT00368654Written as RaptivaHow we know
- A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque PsoriasisCompletedPhase 4Merck KGaA, Darmstadt, GermanyNCT00287118Written as EfalizumabHow we know
- Raptiva and Sirolimus in Islet Transplantation for Type 1 DiabetesTerminatedPhase 1/2University of MinnesotaNCT00672204Written as RaptivaHow we know
- A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal TransplantationWithdrawnPhase 2/3Genentech, Inc.NCT00729768Written as efalizumabHow we know
- A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the ScalpCompletedPhase 4Genentech, Inc.NCT00669214Written as efalizumabHow we know
- Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous SteroidsTerminatedNot applicableUNC Lineberger Comprehensive Cancer CenterNCT00489216Written as efalizumabHow we know
- A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or FeetCompletedPhase 4Genentech, Inc.NCT00312026Written as efalizumabHow we know
- CLEAR Study: Clinical Experience Acquired With Raptiva StudyCompletedPhase 3Merck KGaA, Darmstadt, GermanyNCT00256139Written as RaptivaHow we know
- Efalizumab for Treatment of Patients With Moderate to Severe PsoriasisCompletedPhase 3Merck KGaA, Darmstadt, GermanyNCT00442650Written as EfalizumabHow we know
- Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME StudyWithdrawnPhase 1Johns Hopkins UniversityNCT00676559Written as EfalizumabHow we know
- Efalizumab in the Treatment of Alopecia, Phase IIWithdrawnPhase 2Northwestern UniversityNCT00746980Written as efalizumabHow we know
- Pilot Study of Raptiva to Treat Sjogren's SyndromeTerminatedPhase 2National Institute of Dental and Craniofacial Research (NIDCR)NCT00344448Written as RaptivaHow we know
- A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF AgentCompletedPhase 4Genentech, Inc.NCT00336973Written as efalizumabHow we know
- Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular DegenerationWithdrawnPhase 1Vitreous -Retina- Macula Consultants of New YorkNCT00726466Written as Efalizumab, RanibizumabHow we know
- Beta Cell Rescue in New Onset Type 1 Diabetes With EfalizumabWithdrawnPhase 2Emory UniversityNCT00737763Written as efalizumabHow we know
- A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600gCompletedPhase 3Genentech, Inc.NCT00096603Written as Raptiva (efalizumab)How we know
See all 35 studies that test efalizumab →
Given beside what is tested · 1 — efalizumab is usual care or a partner of the new treatment
Codes
What other systems call efalizumab · ClinicalTrials.gg INT004515
- MeSH (NLM) C472181efalizumabOne source NLM
- UNII (FDA) XX2MN88N5DEFALIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 356988Confirmed FDA, Wikidata
- Wikidata Q418270efalizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C68831EfalizumabOne source FDA
- DrugBank DB00095One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C472181 | efalizumab | One source NLM |
| UNII (FDA) | XX2MN88N5D | EFALIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 356988 | — | Confirmed FDA, Wikidata |
| Wikidata | Q418270 | efalizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C68831 | Efalizumab | One source FDA |
| DrugBank | DB00095 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.